Denali Therapeutics Inc. (DNLI): Price and Financial Metrics

Denali Therapeutics Inc. (DNLI): $24.42

0.08 (+0.33%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

DNLI Price/Volume Stats

Current price $24.42 52-week high $33.33
Prev. close $24.34 52-week low $14.56
Day low $23.82 Volume 767,900
Day high $24.83 Avg. volume 1,069,275
50-day MA $28.07 Dividend yield N/A
200-day MA $22.54 Market Cap 3.51B

DNLI Stock Price Chart Interactive Chart >


Denali Therapeutics Inc. (DNLI) Company Bio


Denali Therapeutics Inc. engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company’s lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson’s disease. It is also developing therapeutics for the treatment of Parkinson’s, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was founded in 2013 and is based in South San Francisco, California.


DNLI Latest News Stream


Event/Time News Detail
Loading, please wait...

DNLI Latest Social Stream


Loading social stream, please wait...

View Full DNLI Social Stream

DNLI Price Returns

1-mo -7.11%
3-mo -1.41%
6-mo 27.12%
1-year 34.92%
3-year -46.05%
5-year 36.50%
YTD 13.79%
2023 -22.83%
2022 -37.65%
2021 -46.75%
2020 380.83%
2019 -15.68%

Continue Researching DNLI

Here are a few links from around the web to help you further your research on Denali Therapeutics Inc's stock as an investment opportunity:

Denali Therapeutics Inc (DNLI) Stock Price | Nasdaq
Denali Therapeutics Inc (DNLI) Stock Quote, History and News - Yahoo Finance
Denali Therapeutics Inc (DNLI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!